Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2010

01-08-2010 | Hepatobiliary Tumors

Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization

Authors: Thierry de Baere, MD, Christophe Teriitehau, MD, Frederic Deschamps, MD, Laurence Catherine, MD, Pramod Rao, MD, Antoine Hakime, MD, Anne Auperin, MD, Diane Goere, MD, Dominique Elias, MD, Lukas Hechelhammer, MD

Published in: Annals of Surgical Oncology | Issue 8/2010

Login to get access

Abstract

Background

To analyze predictive factors of hypertrophy of the nonembolized future remnant liver (FRL) after transhepatic preoperative portal vein embolization (PVE) of the liver to be resected.

Materials and Methods

Age, gender, indocyanin green clearance test, chemotherapy before PVE, type of chemotherapy, operators, extent of PVE, radiofrequency ablation (RFA) associated with PVE, time delay between PVE and surgery, and platelet count were retrospectively evaluated as predictive factors for hypertrophy of FRL in 107 patients with malignant disease in noncirrhotic liver. PVE targeted the right liver lobe [n = 70] or the right liver lobe and segment IV [n = 37] when FRL/total liver volume ratio was below 25% in healthy liver or 40% in altered liver.

Results

After PVE, FRL volume significantly increased by 69%, from 344 ± 156 cm3 to 543 ± 192 cm3 (P < .0001). The degree of hypertrophy was negatively correlated with FRL volume (correlation coefficient = −0.55, P < .0001) and FRL/TFL ratio (correlation coefficient = −0.52, P < .0001) before PVE. Patients, who have undergone chemotherapy with platin agents prior to PVE, demonstrated lower hypertrophy (P = .048).

Conclusion

Hypertrophy after PVE is inversely correlated to initial FRL volume. Hypertrophy of the liver might be influenced by the systemic chemotherapeutic received before PVE.
Literature
1.
Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999;188:304–9.CrossRefPubMed
2.
Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675–80; discussion 680–1.CrossRefPubMed
3.
Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325–30.CrossRefPubMed
4.
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57; discussion 657–8.CrossRefPubMed
5.
Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480–6.CrossRefPubMed
6.
Yigitler C, Farges O, Kianmanesh R, Regimbeau JM, Abdalla EK, Belghiti J. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl. 2003;9:S18–25.CrossRefPubMed
7.
Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803–8.CrossRefPubMed
8.
de Baere T, Roche A, Vavasseur D, Therasse E. Portal vein embolisation: utility for inducing left hepatic lobe hypertrophy before surgery. Radiology. 1993;188:73–7.PubMed
9.
Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.CrossRefPubMed
10.
Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005;16:779–90.PubMed
11.
Yamanaka N, Okamoto E, Kawamura E, Kato T, Oriyama T, Fujimoto J, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology. 1993;18:79–85.CrossRefPubMed
12.
Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686–91; discussion 691–3.CrossRefPubMed
13.
de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V. Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology. 1996;24:1386–91.CrossRefPubMed
14.
Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51:1788–91.PubMed
15.
Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology. 1999;29:1099–105.CrossRefPubMed
16.
Kaido T, Arii S, Shimada Y, Mori A, Imamura M. Portal embolization in various types of liver: novel variables to predict hypertrophy. Hepatogastroenterology. 2003;50:140–5.PubMed
17.
Fujii Y, Shimada H, Endo I, Morioka D, Nagano Y, Miura Y, et al. Risk factors of posthepatectomy liver failure after portal vein embolization. J Hepatobiliary Pancreat Surg. 2003;10:226–32.CrossRefPubMed
18.
Goere D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10:365–70.CrossRefPubMed
19.
Kobayashi S, Nagino M, Yokoyama Y, Nimura Y, Sokabe M. Evaluation of hepatic interleukin-6 secretion following portal vein ligation using a minimal surgical stress model. J Surg Res. 2006;135:27–33.CrossRefPubMed
20.
Nanashima A, Sumida Y, Shibasaki S, Takeshita H, Hidaka S, Sawai T, et al. Parameters associated with changes in liver volume in patients undergoing portal vein embolization. J Surg Res. 2006;133:95–101.CrossRefPubMed
21.
Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:1091–8.CrossRefPubMed
22.
Denys A, Lacombe C, Schneider F, Madoff DC, Doenz F, Qanadli SD, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol. 2005;16:1667–74.PubMed
23.
Covey AM, Tuorto S, Brody LA, Sofocleous CT, Schubert J, von Tengg-Kobligk H, et al. Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol. 2005;185:1620–6.CrossRefPubMed
24.
Nagino M, Ando M, Kamiya J, Uesaka K, Sano T, Nimura Y. Liver regeneration after major hepatectomy for biliary cancer. Br J Surg. 2001;88:1084–91.CrossRefPubMed
25.
Tani M, Tomiya T, Yamada S, Hayashi S, Yahata K, Tamura Y. Regulating factors of liver regeneration after hepatectomy. Cancer Chemother Pharmacol. 1994;33:S29–S32.CrossRefPubMed
26.
Bucher NL, Swaffield MN. The rate of incorporation of labeled thymidine into the deoxyribonucleic acid of regenerating rat liver in relation to the amount of liver excised. Cancer Res. 1964;24:1611–25.PubMed
27.
Yuceturk H, Yagmurdur MC, Gur G, Demirbilek M, Bilezikci B, Turan M, et al. Role of heparin on TNF-alpha and IL-6 levels in liver regeneration after partial hepatic resection. Eur Surg Res. 2007;39:216–21.CrossRefPubMed
28.
Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.CrossRefPubMed
29.
Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.CrossRefPubMed
30.
Beal IK, Anthony S, Papadopoulou A, Hutchins R, Fusai G, Begent R, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol. 2006;79:473–8.CrossRefPubMed
31.
Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247:451–5.CrossRefPubMed
32.
Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.CrossRefPubMed
33.
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765–72.CrossRefPubMed
34.
Nagino M, Kamiya J, Kanai M, Uesaka K, Sano T, Yamamoto H, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery. 2000;127:155–60.CrossRefPubMed
35.
Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery. 2008;144:–74451.
36.
de Baere T, Denys A, Paradis V. Comparison of four embolic materials for portal vein embolization: experimental study in pigs. Eur Radiol. 2009;19:1435–41.CrossRefPubMed
37.
Breen DJ, Rutherford EE, Stedman B, Lee-Elliott C, Hacking CN. Intrahepatic arterioportal shunting and anomalous venous drainage: understanding the CT features in the liver. Eur Radiol. 2004;14:2249–60.CrossRefPubMed
38.
Arai K, Matsui O, Takashima T, Ida M, Nishida Y. Focal spared areas in fatty liver caused by regional decreased portal flow. AJR Am J Roentgenol. 1988;151:300–2.PubMed
39.
Takayasu K, Aoki K, Ichikawa T, Ohmura T, Sekiguchi R, Terauchi T, et al. Aberrant right gastric vein directly communicating with left portal vein system. Incidence and implications. Acta Radiol. 1990;31:575–7.PubMed
40.
Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–7.CrossRefPubMed
Metadata
Title
Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization
Authors
Thierry de Baere, MD
Christophe Teriitehau, MD
Frederic Deschamps, MD
Laurence Catherine, MD
Pramod Rao, MD
Antoine Hakime, MD
Anne Auperin, MD
Diane Goere, MD
Dominique Elias, MD
Lukas Hechelhammer, MD
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0979-2

Other articles of this Issue 8/2010

Annals of Surgical Oncology 8/2010 Go to the issue

Endocrine Tumors

Clinical Presentation, Staging and Long-Term Evolution of Parathyroid Cancer

Melanomas

Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease

Gastrointestinal Oncology

Laparoscopy-Assisted Distal Gastrectomy with Jejunal Pouch Interposition

Breast Oncology

Intraoperative Imprint Cytology Examination of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy in Breast Cancer Patients

Head and Neck Oncology

Improvements in the Staging of Cutaneous Squamous-Cell Carcinoma in the 7th Edition of the AJCC Cancer Staging Manual

Pancreatic Tumors

Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration